Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
gevokizumab
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Erosive Osteoarthritis, Osteoarthritis, Osteoarthritis of the Hand
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of hand osteoarthritis
- Joint tenderness and/or redness
- At least one erosion by X-ray (as determined by the central reader)
- Contraceptive measures adequate to prevent pregnancy during the study
Exclusion Criteria:
- History of inflammatory disease other than hand EOA including: secondary post-traumatic OA; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia
- History of gout, pseudogout, or hemochromatosis
- History of allergic or anaphylactic reactions to monoclonal antibodies
- History of recurrent or chronic systemic infections
- Known allergy to acetaminophen
- Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
gevokizumab
Arm Description
Outcomes
Primary Outcome Measures
Percent change from baseline in AUSCAN pain score at Day 84
The Australian/Canadian (AUSCAN) Osteoarthritis Hand Index is a self-report assessment of pain, stiffness, and function in patients with hand osteoarthritis.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01683396
Brief Title
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Official Title
A Phase 2 Proof-of-Concept Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand
Study Type
Interventional
2. Study Status
Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
XOMA (US) LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of active inflammatory, erosive osteoarthritis of the hand.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Erosive Osteoarthritis, Osteoarthritis, Osteoarthritis of the Hand
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
87 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
gevokizumab
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Solution for subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
gevokizumab
Intervention Description
Solution for subcutaneous injection
Primary Outcome Measure Information:
Title
Percent change from baseline in AUSCAN pain score at Day 84
Description
The Australian/Canadian (AUSCAN) Osteoarthritis Hand Index is a self-report assessment of pain, stiffness, and function in patients with hand osteoarthritis.
Time Frame
Baseline and Day 84
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of hand osteoarthritis
Joint tenderness and/or redness
At least one erosion by X-ray (as determined by the central reader)
Contraceptive measures adequate to prevent pregnancy during the study
Exclusion Criteria:
History of inflammatory disease other than hand EOA including: secondary post-traumatic OA; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia
History of gout, pseudogout, or hemochromatosis
History of allergic or anaphylactic reactions to monoclonal antibodies
History of recurrent or chronic systemic infections
Known allergy to acetaminophen
Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
Other protocol-defined inclusion/exclusion criteria may apply
Facility Information:
City
Huntsville
State/Province
Alabama
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Little Rock
State/Province
Arkansas
Country
United States
City
Roseville
State/Province
California
Country
United States
City
Sacramento
State/Province
California
Country
United States
City
Santa Monica
State/Province
California
Country
United States
City
Van Nuys
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Pinellas Park
State/Province
Florida
Country
United States
City
Sarasota
State/Province
Florida
Country
United States
City
Vero Beach
State/Province
Florida
Country
United States
City
West Palm Beach
State/Province
Florida
Country
United States
City
Wichita
State/Province
Kansas
Country
United States
City
Reno
State/Province
Nevada
Country
United States
City
New York
State/Province
New York
Country
United States
City
Rochester
State/Province
New York
Country
United States
City
Raleigh
State/Province
North Carolina
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Duncansville
State/Province
Pennsylvania
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Waco
State/Province
Texas
Country
United States
City
Charlottesville
State/Province
Virginia
Country
United States
City
Norfolk
State/Province
Virginia
Country
United States
City
Franklin
State/Province
Wisconsin
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
We'll reach out to this number within 24 hrs